• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Akouos Inc.

    12/12/22 4:11:07 PM ET
    $AKUS
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AKUS alert in real time by email
    15-12G 1 d412684d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-39343

     

     

    AKOUOS, INC.

    (Exact name of registrant as specified in its charter)

     

     

    645 Summer Street, Suite 200

    Boston, Massachusetts 02210

    Telephone: (857) 410-1818

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common stock, $0.0001 par value per share

    (Title of each class of securities covered by this Form)

    None

    (Title of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: One holder

    Pursuant to the requirements of the Securities Exchange Act of 1934, Akouos, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: December 12, 2022

       

    Akouos, Inc.

        By:  

    /s/ Philip L. Johnson

        Name:   Philip L. Johnson
        Title:   President

     

     

     

    Get the next $AKUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKUS

    DatePrice TargetRatingAnalyst
    9/29/2022$12.00Outperform
    William Blair
    More analyst ratings

    $AKUS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Akouos Inc.

      15-12G - Akouos, Inc. (0001722271) (Filer)

      12/12/22 4:11:07 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form EFFECT filed by Akouos Inc.

      EFFECT - Akouos, Inc. (0001722271) (Filer)

      12/6/22 12:15:08 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form POS AM filed by Akouos Inc.

      POS AM - Akouos, Inc. (0001722271) (Filer)

      12/1/22 4:42:00 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

      INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ:AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. "Akouos brings more top-tier talent and an important pipeline to Lilly's Institute for Genetic Medicine that will further accelerate our work to advance genetic medicines for people living with difficult-to-treat diseases," said Andrew C. Adams, Ph.D., senior vice president of genetic medicine

      12/1/22 8:41:00 AM ET
      $AKUS
      $LLY
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly and Akouos Announce Expiration of Akouos Tender Offer

      INDIANAPOLIS and BOSTON, Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Akouos, Inc. (NASDAQ:AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones (the "Offer"), expire

      11/30/22 6:50:00 AM ET
      $AKUS
      $LLY
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

      -Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. "This has been a transformative year for us, and we've achieved

      11/14/22 7:15:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Akouos with a new price target

      William Blair initiated coverage of Akouos with a rating of Outperform and set a new price target of $12.00

      9/29/22 9:08:33 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • HC Wainwright & Co. initiated coverage on Akouos with a new price target

      HC Wainwright & Co. initiated coverage of Akouos with a rating of Buy and set a new price target of $25.00

      4/27/21 6:28:58 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos downgraded by BofA Securities with a new price target

      BofA Securities downgraded Akouos from Buy to Neutral and set a new price target of $20.00 from $24.00 previously

      3/30/21 6:33:57 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Walker Paul Edward (tax withholding)

      4 - Akouos, Inc. (0001722271) (Issuer)

      12/2/22 5:13:26 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Sonsini Peter W. (tax withholding)

      4 - Akouos, Inc. (0001722271) (Issuer)

      12/2/22 5:12:13 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Sandell Scott D to satisfy withholding tax

      4 - Akouos, Inc. (0001722271) (Issuer)

      12/2/22 5:10:58 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer

      BOSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer. Dr. Tward is a surgeon and a scientist with deep experience in genetics, genomics, gene delivery, high-throughput sequencing technologies, and the clinical care of patients with conditions of the ear and skull base. Dr. Tward was previously a member of the Akouos scientific advisory board since 2018. As chief scientific officer, he will lead the research team, and provide strategic scie

      3/10/22 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Appoints Stacy Price as Chief Technical Officer

      BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Stacy Price as chief technical officer. Ms. Price brings to Akouos more than 25 years of experience managing clinical and commercial biotechnology manufacturing and technical operations for a wide range of therapeutic modalities, including gene therapy. At Akouos, she will be responsible for the strategy and operations of vector development and manufacturing, as well as device development and engineering. "We are excited to welcome Stacy to

      11/1/21 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Appoints Dr. Kathy Reape as Chief Development Officer

      BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Dr. Kathy Reape as chief development officer. Dr. Reape brings over 20 years of experience in the pharmaceutical industry, including significant gene therapy translational and development expertise, to Akouos. "We welcome Dr. Reape to the Akouos team at this exciting time in the company's growth, as we continue to advance the AK-OTOF and AK-antiVEGF programs towards our planned IND submissions in 2022," said Manny Simons, Ph.D., M.B.A., co-f

      5/7/21 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Akouos Inc. (Amendment)

      SC 13G/A - Akouos, Inc. (0001722271) (Subject)

      2/14/23 3:32:27 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Akouos Inc. (Amendment)

      SC 13G/A - Akouos, Inc. (0001722271) (Subject)

      2/10/23 1:59:31 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Akouos Inc. (Amendment)

      SC 13G/A - Akouos, Inc. (0001722271) (Subject)

      1/10/23 12:48:26 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Financials

    Live finance-specific insights

    See more
    • Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

      -Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. "This has been a transformative year for us, and we've achieved

      11/14/22 7:15:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights

      Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expression in the inner ear Received a notice of allowance from USPTO for claims covering compositions, including AK-OTOF, and methods of treatment useful for OTOF-mediated hearing lossEnded Q2 2022 with a strong cash position of $192.9 million BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing los

      8/15/22 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights

      - Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at ASGCT supporting the planned clinical development of AK-OTOF and highlighting the potential use of microRNA target sites in AAV vectors for regulated gene expression in the inner ear - Presented new nonclinical data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions -Ended the first quarter with a strong cash position of $209.1 million BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potenti

      5/12/22 7:45:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary